William Scott Melvin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William Scott Melvin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Dean J. Mikami
The Ohio State University Medical Center
3 shared publicationsJeffrey W. Hazey
Center for Minimally Invasive Surgery, Department of Surgery, The Ohio State University, Columbus
3 shared publicationsSimon Bergman
McGill University Health Center
3 shared publications- David B. Renton
The Ohio State University Wexner Medical Center
2 shared publications - Kevin M. Reavis
Division of General Surgery, The Ohio State University, RM N 729 Doan Hall, 410 W. Tenth Avenue, Columbus, OH 43210, USA
2 shared publications Rebecca Dettorre
The Ohio State University Medical Center
2 shared publications
Latest Publications
- 27 March 2013
- Published by Springer Nature
- p. 157-166
Endoscopic Considerations in Gastroesophageal Reflux Disease
- 27 March 2013
- Published by Springer Nature
- p. 157-166
Endoscopic Considerations in Gastroesophageal Reflux Disease
- 22 February 2012
- Published by Springer Nature
- p. 191-203
16. Robotics in Laparoscopic and Thoracoscopic Surgery
- 22 February 2012
- Published by Springer Nature
- p. 191-203
16. Robotics in Laparoscopic and Thoracoscopic Surgery
- 1 September 2011
- Published by American Medical Association (AMA)
- Vol. 146 (9) , 1093-1094
Modern Treatment for Gastroesophageal Reflux Disease
Opinion from JAMA Surgery — Modern Treatment for Gastroesophageal Reflux Disease — Surgery vs Medication
- 1 September 2011
- Published by American Medical Association (AMA)
- Vol. 146 (9) , 1093-1094
Modern Treatment for Gastroesophageal Reflux Disease
Opinion from JAMA Surgery — Modern Treatment for Gastroesophageal Reflux Disease — Surgery vs Medication
- 27 August 2011
- Published by Springer Nature
- p. 207-221
Common Endoscopic Complications: Recognition and Management
- 27 August 2011
- Published by Springer Nature
- p. 207-221
Common Endoscopic Complications: Recognition and Management
- 23 December 2010
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (2) , 330-338
Lubiprostone Reverses the Inhibitory Action of Morphine on Mucosal Secretion in Human Small Intestine
Treatments with morphine or opioid agonists cause constipation. Lubiprostone is approved for treatment of adult idiopathic constipation and constipation-predominant IBS in adult women. We tested whether lubiprostone can reverse morphine-suppression of mucosal secretion in human intestine and explored the mechanism of action.
- 23 December 2010
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (2) , 330-338
Lubiprostone Reverses the Inhibitory Action of Morphine on Mucosal Secretion in Human Small Intestine
Treatments with morphine or opioid agonists cause constipation. Lubiprostone is approved for treatment of adult idiopathic constipation and constipation-predominant IBS in adult women. We tested whether lubiprostone can reverse morphine-suppression of mucosal secretion in human intestine and explored the mechanism of action.
- 25 September 2009
- Published by SAGE Publications in Surgical Innovation
- Vol. 16 (3) , 237-242
Barbed Suture for Gastrointestinal Closure: A Randomized Control Trial
In an effort to make laparoscopic suturing more efficient, the V-Loc advanced wound closure device (Covidien, Mansfield, MA) has been produced. This device is a self-anchoring barbed suture that obviates the need for knot tying. The goal of this initial feasibility study was to investigate the use of the barbed suture in gastrointestinal enterotomy closure. A randomized study of 12 pigs comparing enterotomy closure with barbed versus a nonbarbed suture of similar tensile strength was performed. To this end, 25 mm enterotomies were made in the stomach (1 control, 1 treatment), jejunum (2 controls, 2 treatments), and descending colon (1 control, 1 treatment). Animals were killed at 3, 7, and 14 days postoperatively (4 each group) and their gastrointestinal tracts harvested; 6 of the 8 enterotomies from each pig underwent burst strength testing. The remaining 2 were fixed in formalin and sent for histological examination. All 12 pigs survived until they were killed without any major complications. Enterotomy closure with barbed suture revealed adhesion scores, burst strength pressures, and histology scores that were similar to those for the control. Jejunal closures resulted in 6 failures at 7 days (3 control, 3 barbed) and 4 failures at 14 days (2 control, 2 barbed). The barbed suture significantly reduced suturing time in the stomach, jejunum, and colon. The V-Loc wound closure device appears to offer comparable gastrointestinal closure to 3-0 Maxon while being significantly faster. Further studies with V-Loc are required to assess its use in laparoscopic surgery.
- 25 September 2009
- Published by SAGE Publications in Surgical Innovation
- Vol. 16 (3) , 237-242
Barbed Suture for Gastrointestinal Closure: A Randomized Control Trial
In an effort to make laparoscopic suturing more efficient, the V-Loc advanced wound closure device (Covidien, Mansfield, MA) has been produced. This device is a self-anchoring barbed suture that obviates the need for knot tying. The goal of this initial feasibility study was to investigate the use of the barbed suture in gastrointestinal enterotomy closure. A randomized study of 12 pigs comparing enterotomy closure with barbed versus a nonbarbed suture of similar tensile strength was performed. To this end, 25 mm enterotomies were made in the stomach (1 control, 1 treatment), jejunum (2 controls, 2 treatments), and descending colon (1 control, 1 treatment). Animals were killed at 3, 7, and 14 days postoperatively (4 each group) and their gastrointestinal tracts harvested; 6 of the 8 enterotomies from each pig underwent burst strength testing. The remaining 2 were fixed in formalin and sent for histological examination. All 12 pigs survived until they were killed without any major complications. Enterotomy closure with barbed suture revealed adhesion scores, burst strength pressures, and histology scores that were similar to those for the control. Jejunal closures resulted in 6 failures at 7 days (3 control, 3 barbed) and 4 failures at 14 days (2 control, 2 barbed). The barbed suture significantly reduced suturing time in the stomach, jejunum, and colon. The V-Loc wound closure device appears to offer comparable gastrointestinal closure to 3-0 Maxon while being significantly faster. Further studies with V-Loc are required to assess its use in laparoscopic surgery.
- 3 September 2009
- Published by Springer Nature in Surgical Endoscopy
- Vol. 24 (4) , 854-858
Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population
EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. The study enrolled 26 patients with a mean age of 45 years. The patients included 16 women (62%) with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett’s esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29–137 min), and the length of hospital stay was 1 day (range, 0–6 days). The postoperative valve circumference was 217º, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34–17; P = 0.002) and Velanovich scores (22–10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiring Nissen fundoplication, and there was one late death unrelated to the procedure. This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow-up evaluation and objective testing are required.
- 3 September 2009
- Published by Springer Nature in Surgical Endoscopy
- Vol. 24 (4) , 854-858
Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population
EsophyX is an endolumenal approach to the treatment of gastroesophageal reflux disease (GERD). This report describes one of the earliest and largest North American experiences with this device. Prospective data were gathered on consecutive patients undergoing EsophyX fundoplication for a 1-year period between September 2007 and March 2009. During this time, the procedure evolved to the current technique. A P value less than 0.05 was considered significant. The study enrolled 26 patients with a mean age of 45 years. The patients included 16 women (62%) with a mean body mass index (BMI) of 28 and an American Society Anesthesiology (ASA) classification of 2. These patients included 11 with associated small hiatal hernias, 3 with Barrett’s esophagus, and 5 with esophageal dysmotility. The procedure time was 65 min (range, 29–137 min), and the length of hospital stay was 1 day (range, 0–6 days). The postoperative valve circumference was 217º, and the valve length was 2.7 cm. Two complications of postoperative bleed occurred, requiring transfusion. The mean follow-up period was 10 months. Comparison of pre- and postoperative Anvari scores (34–17; P = 0.002) and Velanovich scores (22–10; P = 0.0007) showed significant decreases. Although 68% of the patients were still taking antireflux medications, 21% had reduced their dose by half. Three patients had persistent symptoms requiring Nissen fundoplication, and there was one late death unrelated to the procedure. This study represents an initial single-institution experience with EsophyX. According to the findings, 53% of the patients had either discontinued their antireflux medication (32%) or had decreased their dose by half (21%). Both symptoms and health-related quality-of-life (HRQL) scores significantly improved after treatment. Further follow-up evaluation and objective testing are required.
- 31 October 2008
- Published by Elsevier in Surgical Clinics of North America
- Vol. 88 (5) , 1131-1148
Natural Orifice Translumenal Endoscopic Surgery
- 31 October 2008
- Published by Elsevier in Surgical Clinics of North America
- Vol. 88 (5) , 1131-1148
Natural Orifice Translumenal Endoscopic Surgery
- 14 September 2008
- Published by SAGE Publications in Surgical Innovation
- Vol. 15 (4) , 297-301
Radiofrequency Energy Delivery to the Lower Esophageal Sphincter (Stretta Procedure) Does Not Provide Long-term Symptom Control
The Stretta procedure (radiofrequency energy application to the lower esophageal sphincter) is a unique endoluminal technique for the management of gastroesophageal reflux. This article reports on the long-term effectiveness of the Stretta procedure in patients with significant gastroesophageal reflux disease (GERD) referred to a surgical practice. Patients who underwent Stretta with a minimum of 36 months follow-up were included. Thirty-two patients with an average follow-up of 53 months were included; 19 proceeded to anti-reflux surgery. Those not undergoing surgery showed a significant improvement in their GERD satisfaction from 3.14 to 1.46 (P = .0006) but had significantly lower preprocedure heartburn scores (2.43) than those who proceeded to surgery (3.66, P = .0401). The Stretta procedure was effective in reducing symptoms in 40% of patients. Responders had less severe preoperative heartburn. Radiofrequency energy delivery to the lower esophageal sphincter may be effective in selected patients for the treatment of gastroesophageal reflux.
- 14 September 2008
- Published by SAGE Publications in Surgical Innovation
- Vol. 15 (4) , 297-301
Radiofrequency Energy Delivery to the Lower Esophageal Sphincter (Stretta Procedure) Does Not Provide Long-term Symptom Control
The Stretta procedure (radiofrequency energy application to the lower esophageal sphincter) is a unique endoluminal technique for the management of gastroesophageal reflux. This article reports on the long-term effectiveness of the Stretta procedure in patients with significant gastroesophageal reflux disease (GERD) referred to a surgical practice. Patients who underwent Stretta with a minimum of 36 months follow-up were included. Thirty-two patients with an average follow-up of 53 months were included; 19 proceeded to anti-reflux surgery. Those not undergoing surgery showed a significant improvement in their GERD satisfaction from 3.14 to 1.46 (P = .0006) but had significantly lower preprocedure heartburn scores (2.43) than those who proceeded to surgery (3.66, P = .0401). The Stretta procedure was effective in reducing symptoms in 40% of patients. Responders had less severe preoperative heartburn. Radiofrequency energy delivery to the lower esophageal sphincter may be effective in selected patients for the treatment of gastroesophageal reflux.
- 9 July 2008
- Published by SAGE Publications in Surgical Innovation
- Vol. 15 (3) , 166-170
Endolumenal Fundoplication With EsophyX: The Initial North American Experience
EsophyX is a novel endolumenal therapeutic option for the treatment of gastroesophageal reflux disease (GERD). The device is passed into the stomach, where it deploys a series of full-thickness fasteners to create a neogastroesophageal valve. The objective of this study was to demonstrate the safety and characterize the effectiveness of this approach in the initial North American experience. This is a retrospective study of consecutive patients with GERD who had undergone endolumenal fundoplication with the EsophyX device. At follow-up, proton pump inhibitor usage was elicited and 2 validated questionnaires were administered measuring GERD health—related quality of life (range 0-50) and symptom severity (range 0-72). In limited preliminary evaluation, the initial North American experience with endolumenal fundoplication using the EsophyX device is that it appears to be safe and provides moderate effectiveness in treating the symptoms of GERD. Further studies comparing this technique with conventional medical and surgical therapies are necessary.
- 9 July 2008
- Published by SAGE Publications in Surgical Innovation
- Vol. 15 (3) , 166-170
Endolumenal Fundoplication With EsophyX: The Initial North American Experience
EsophyX is a novel endolumenal therapeutic option for the treatment of gastroesophageal reflux disease (GERD). The device is passed into the stomach, where it deploys a series of full-thickness fasteners to create a neogastroesophageal valve. The objective of this study was to demonstrate the safety and characterize the effectiveness of this approach in the initial North American experience. This is a retrospective study of consecutive patients with GERD who had undergone endolumenal fundoplication with the EsophyX device. At follow-up, proton pump inhibitor usage was elicited and 2 validated questionnaires were administered measuring GERD health—related quality of life (range 0-50) and symptom severity (range 0-72). In limited preliminary evaluation, the initial North American experience with endolumenal fundoplication using the EsophyX device is that it appears to be safe and provides moderate effectiveness in treating the symptoms of GERD. Further studies comparing this technique with conventional medical and surgical therapies are necessary.